'Stronger than Wegovy'! 'Mounjaro' Launches in Korea in August (Price, Efficacy, Side Effects Summary)

"The ultimate weight loss injection is coming!"

Wegovy, the obesity treatment drug that swept Korea last year. **'Mounjaro (tirzepatide)'**, dubbed the 'next-generation ultimate game-changer' that will surpass Wegovy's dominance, is finally **officially launching in Korea this month (August)**. With rumors spreading that it's "even more effective than Wegovy," many dieters are already happily(?) wondering if they should "switch over." So, what makes Mounjaro different, and by how much? From price to efficacy and side effects! We've meticulously summarized everything you're most curious about.

1. What Makes Mounjaro Different? (GLP-1 + GIP)

Mounjaro is called 'next-generation' because of its ingredients.

Wegovy: A single ingredient called 'GLP-1' helps suppress appetite and maintain satiety.
Mounjaro: An **'agonist with dual action'** that adds an ingredient called **'GIP'** to 'GLP-1'. GIP promotes insulin secretion and reduces fat accumulation, powerfully synergizing with GLP-1's weight loss effects.

Clinical trial results showed that while Wegovy had an average weight loss effect of around 15%, Mounjaro showed an astonishing weight loss effect of **up to 22.5%**, heralding the arrival of the 'ultimate game-changer'.

2. The Most Important 'Price' and 'Launch Date'

Here's the price and launch information you're most curious about.

Launch Date: Prescription begins at hospitals from **mid-August 2025**.
Domestic Approval Status (⭐Very Important⭐): Currently, domestic MFDS approval is limited to the purpose of **'treating Type 2 diabetes'**. This means that general dieters without a diabetes diagnosis **cannot yet be prescribed for obesity treatment.** (Obesity treatment indication expected to be approved by end of year or early next year)
Estimated Price: Based on non-reimbursed costs, the monthly (4-week) treatment cost is expected to range from **approximately ₩370,000 to ₩400,000**. This is somewhat cheaper than Wegovy (around ₩500,000).

3. Side Effects, Similar to Wegovy, But…

Like Wegovy, Mounjaro's most commonly reported side effects are gastrointestinal issues such as **nausea, vomiting, diarrhea, and constipation**. Most appear in the early stages of administration and disappear as the body adapts.

However, it is a specialized prescription drug that **must be used under a doctor's diagnosis and prescription**, as rare cases of pancreatitis or gallbladder disease can occur, and its use is prohibited for individuals with a history of medullary thyroid cancer. This should not be forgotten.

The Arrival of a 'Game Changer', But Caution is Essential

More powerful effects and a slightly lower price. Mounjaro is clearly a strong 'game changer' that could threaten Wegovy. However, it currently has a clear limitation in Korea: it cannot yet be prescribed for 'obesity treatment'.

If it receives approval for the obesity treatment indication in the future, it is expected to bring significant changes to the domestic diet and obesity treatment market. However, as Mounjaro is also a specialized prescription drug, it is important to develop the optimal treatment plan through thorough consultation with a doctor.

#Mounjaro #Wegovy #DietInjection #ObesityTreatment #GLP1 #GIP #DiabetesTreatment #NewDrug #MedicalInformation #Diet #WeightLoss #Health #MFDS #EliLilly #NonReimbursed #Obesity #MedicalInfo

'Stronger than Wegovy'! 'Mounjaro' Launches in Korea in August (Price, Efficacy, Side Effects Summary)